S&P 500   4,583.97 (-0.04%)
DOW   36,122.12 (+0.01%)
QQQ   390.67 (+0.06%)
AAPL   194.54 (+0.14%)
MSFT   372.11 (+0.31%)
META   328.98 (+0.73%)
GOOGL   134.87 (-1.50%)
AMZN   146.49 (-0.27%)
TSLA   243.74 (+0.45%)
NVDA   475.82 (+2.12%)
NIO   7.47 (-0.27%)
BABA   72.01 (-0.44%)
AMD   128.74 (+0.29%)
T   16.95 (-0.82%)
F   11.01 (+1.76%)
MU   74.43 (+1.06%)
CGC   0.77 (+6.58%)
GE   120.03 (+0.46%)
DIS   93.12 (+0.83%)
AMC   7.00 (+2.64%)
PFE   28.81 (+0.63%)
PYPL   59.20 (+1.23%)
XOM   99.35 (+0.94%)
S&P 500   4,583.97 (-0.04%)
DOW   36,122.12 (+0.01%)
QQQ   390.67 (+0.06%)
AAPL   194.54 (+0.14%)
MSFT   372.11 (+0.31%)
META   328.98 (+0.73%)
GOOGL   134.87 (-1.50%)
AMZN   146.49 (-0.27%)
TSLA   243.74 (+0.45%)
NVDA   475.82 (+2.12%)
NIO   7.47 (-0.27%)
BABA   72.01 (-0.44%)
AMD   128.74 (+0.29%)
T   16.95 (-0.82%)
F   11.01 (+1.76%)
MU   74.43 (+1.06%)
CGC   0.77 (+6.58%)
GE   120.03 (+0.46%)
DIS   93.12 (+0.83%)
AMC   7.00 (+2.64%)
PFE   28.81 (+0.63%)
PYPL   59.20 (+1.23%)
XOM   99.35 (+0.94%)
S&P 500   4,583.97 (-0.04%)
DOW   36,122.12 (+0.01%)
QQQ   390.67 (+0.06%)
AAPL   194.54 (+0.14%)
MSFT   372.11 (+0.31%)
META   328.98 (+0.73%)
GOOGL   134.87 (-1.50%)
AMZN   146.49 (-0.27%)
TSLA   243.74 (+0.45%)
NVDA   475.82 (+2.12%)
NIO   7.47 (-0.27%)
BABA   72.01 (-0.44%)
AMD   128.74 (+0.29%)
T   16.95 (-0.82%)
F   11.01 (+1.76%)
MU   74.43 (+1.06%)
CGC   0.77 (+6.58%)
GE   120.03 (+0.46%)
DIS   93.12 (+0.83%)
AMC   7.00 (+2.64%)
PFE   28.81 (+0.63%)
PYPL   59.20 (+1.23%)
XOM   99.35 (+0.94%)
S&P 500   4,583.97 (-0.04%)
DOW   36,122.12 (+0.01%)
QQQ   390.67 (+0.06%)
AAPL   194.54 (+0.14%)
MSFT   372.11 (+0.31%)
META   328.98 (+0.73%)
GOOGL   134.87 (-1.50%)
AMZN   146.49 (-0.27%)
TSLA   243.74 (+0.45%)
NVDA   475.82 (+2.12%)
NIO   7.47 (-0.27%)
BABA   72.01 (-0.44%)
AMD   128.74 (+0.29%)
T   16.95 (-0.82%)
F   11.01 (+1.76%)
MU   74.43 (+1.06%)
CGC   0.77 (+6.58%)
GE   120.03 (+0.46%)
DIS   93.12 (+0.83%)
AMC   7.00 (+2.64%)
PFE   28.81 (+0.63%)
PYPL   59.20 (+1.23%)
XOM   99.35 (+0.94%)

Assembly Biosciences Stock Price, News & Analysis (NASDAQ:ASMB)

$0.76
+0.02 (+2.21%)
(As of 11:21 AM ET)
Compare
Today's Range
$0.72
$0.76
50-Day Range
$0.65
$1.25
52-Week Range
$0.64
$1.78
Volume
97,139 shs
Average Volume
653,471 shs
Market Capitalization
$49.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.50

Assembly Biosciences MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
102.0% Upside
$1.50 Price Target
Short Interest
Healthy
2.84% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.71
Upright™ Environmental Score
News Sentiment
0.05mentions of Assembly Biosciences in the last 14 days
Based on 43 Articles This Week
Insider Trading
Selling Shares
$3,403 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.19) to ($1.23) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

305th out of 960 stocks

Pharmaceutical Preparations Industry

93rd out of 381 stocks


ASMB stock logo

About Assembly Biosciences Stock (NASDAQ:ASMB)

Assembly Biosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study. It is also involved in novel small molecule approaches for HBV and hepatitis delta virus (HDV) comprising an orally bioavailable HBV/HDV entry inhibitor and liver-focused interferon-a receptor agonist. In addition, the company develops Herpesvirus programs, such as ABI-5366 HSV-2, a long-acting helicase inhibitor; and pan-herpes non-nucleoside polymerase inhibitors for transplant-associated infections. Further, Assembly Biosciences, Inc. has collaboration agreement with BeiGene, Ltd. to develop and commercialize the novel core inhibitor product candidates for chronic HBV infection in the People's Republic of China, Hong Kong, Taiwan, and Macau; and clinical trial collaboration agreement with Arbutus Biopharma Corporation to conduct a randomized, multi-center, and open-label clinical trials, as well as agreement with Antios Therapeutics, Inc. for triple combination therapy. The company also has license agreement with Indiana University Research and Technology Corporation for HBV research, as well as a partnership with Gilead Sciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

ASMB Stock Price History

ASMB Stock News Headlines

Countries Are Investing Heavily Into Securing Energy Independence
There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.
Countries Are Investing Heavily Into Securing Energy Independence
There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.
Meeting on future of States Assembly
See More Headlines
Receive ASMB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Assembly Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
12/08/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/27/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:ASMB
CUSIP
92282210
Employees
68
Year Founded
2005

Price Target and Rating

Average Stock Price Target
$1.50
High Stock Price Target
$1.50
Low Stock Price Target
$1.50
Potential Upside/Downside
+107.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-93,090,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$6.25 million
Book Value
$1.69 per share

Miscellaneous

Free Float
62,818,000
Market Cap
$47.46 million
Optionable
Optionable
Beta
0.50

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Jason A. Okazaki (Age 47)
    CEO, President & Director
    Comp: $869.28k
  • Dr. William E. Delaney IV (Age 51)
    Ph.D., Chief Scientific Officer
    Comp: $664.4k
  • Dr. Uri A. Lopatin M.D. (Age 51)
    Co-Founder and Clinical & Scientific Advisor
    Comp: $608.55k
  • Dr. Adam Zlotnick
    Co-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory Board
  • Jeanette M Bjorkquist
    Executive Director of Accounting & Treasury
  • Shannon Ryan
    Senior Vice President of Investor Relations, Corporate Affairs & Alliance Management
  • Ms. Jennifer A. Troia MHROD
    SHRM-SCP, SPHR, Chief Human Resources Officer
  • Dr. Nicole S. White Ph.D.
    Chief Manufacturing Officer
  • Dr. Anuj Gaggar M.D.
    Ph.D., Chief Medical Officer
  • Mr. Thomas E. Rollins (Age 67)
    Executive Officer
    Comp: $472.55k














ASMB Stock Analysis - Frequently Asked Questions

Should I buy or sell Assembly Biosciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ASMB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ASMB, but not buy additional shares or sell existing shares.
View ASMB analyst ratings
or view top-rated stocks.

What is Assembly Biosciences' stock price target for 2024?

1 equities research analysts have issued 1-year price targets for Assembly Biosciences' stock. Their ASMB share price targets range from $1.50 to $1.50. On average, they anticipate the company's stock price to reach $1.50 in the next year. This suggests a possible upside of 102.0% from the stock's current price.
View analysts price targets for ASMB
or view top-rated stocks among Wall Street analysts.

How have ASMB shares performed in 2023?

Assembly Biosciences' stock was trading at $1.30 at the beginning of 2023. Since then, ASMB stock has decreased by 42.9% and is now trading at $0.7426.
View the best growth stocks for 2023 here
.

Are investors shorting Assembly Biosciences?

Assembly Biosciences saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 649,700 shares, a drop of 17.3% from the October 31st total of 785,300 shares. Based on an average trading volume of 1,880,000 shares, the short-interest ratio is presently 0.3 days. Approximately 2.8% of the company's shares are short sold.
View Assembly Biosciences' Short Interest
.

When is Assembly Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024.
View our ASMB earnings forecast
.

How were Assembly Biosciences' earnings last quarter?

Assembly Biosciences, Inc. (NASDAQ:ASMB) issued its quarterly earnings data on Wednesday, November, 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by $0.04.

What is John McHutchison's approval rating as Assembly Biosciences' CEO?

8 employees have rated Assembly Biosciences Chief Executive Officer John McHutchison on Glassdoor.com. John McHutchison has an approval rating of 80% among the company's employees. 76.0% of employees surveyed would recommend working at Assembly Biosciences to a friend.

What other stocks do shareholders of Assembly Biosciences own?
Who are Assembly Biosciences' major shareholders?

Assembly Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Hudson Bay Capital Management LP (0.30%), Acadian Asset Management LLC (0.13%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Jacqueline Sybil Papkoff, Jason A Okazaki, Jeanette M Bjorkquist, John G Mchutchison, Luisa M Stamm, Michael P Samar, Nicole S White, Timothy A Springer, William E Iv Delaney and William E Iv Delaney.
View institutional ownership trends
.

How do I buy shares of Assembly Biosciences?

Shares of ASMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ASMB) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -